CompuGroup Medical Innovates Amid Q3 Earnings Decline

CompuGroup Medical SE & Co. KGaA, a major player in e-health solutions, reports a slight revenue dip to EUR 283.4 million in Q3 2024, nearly stable year-on-year despite previous one-off effects. One-time revenues dropped 16%, while recurring revenues rose 6%, now forming 75% of total revenues.

Adjusted EBITDA fell by 12% to EUR 54.9 million, with a margin of 19%, reflecting investments in innovation. R&D expenses rose to EUR 62.4 million. New product launches include the CGM ONE and CGM STELLA.

Adjusted earnings per share hit EUR 0.35, while free cash flow rose to EUR 17.3 million. Net debt increased to EUR 777.0 million.

Slight growth in the AIS segment contrasts with a decline in the HIS segment revenues. Pharmacy segment revenues also fell, influenced by past one-off revenues.